Metagenomi Therapeutics Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, Metagenomi Therapeutics stock has a consensus rating of "Buy" and an average price target of $8.00. The average 1-year stock price forecast is 566.67% higher than the current stock price, while the lowest is $7.00 (+483.33%) and the highest is $9.00 (+650.00%).

Price Target: $8.00 (+566.67%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$7.00	$8.00	$8.00	$9.00
Change	+483.33%	+566.67%	+566.67%	+650.00%

* Price targets were last updated on May 13, 2026.

Analyst Ratings

The average analyst rating for Metagenomi Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Nov '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	4	4	4	4	4	3
Buy	0	0	0	0	0	0
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	5	5	5	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Geulah Livshits Chardan Capital	Chardan Capital	Buy Reiterates $7	Buy	Reiterates	$7	+483.33%	May 13, 2026
Yanan Zhu Wells Fargo	Wells Fargo	Buy Maintains $12 → $9	Buy	Maintains	$12 → $9	+650.00%	May 12, 2026
Joseph Thome TD Cowen	TD Cowen	Buy Maintains n/a	Buy	Maintains	n/a	n/a	May 11, 2026

Financial Forecast

Revenue This Year

12.15M

from 25.21M

-51.81%

from 25.21M

Revenue Next Year

12.52M

from 12.15M

3.09%

from 12.15M

EPS This Year

-2.11

from -2.36

EPS Next Year

-1.47

from -2.11

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	243.00K	17.20M	44.76M	52.30M	25.21M	12.15M
Revenue Growth	-	6,978.19%	160.21%	16.85%	-51.79%	-51.81%
Operating Income	-23.95M	-44.64M	-78.49M	-88.90M	-96.01M	-94.37M
Net Income	-21.44M	-43.59M	-68.26M	-78.06M	-87.87M	-89.86M
EPS	-	-	-	-	-2.36	-2.11
Free Cash Flow	-	-19.71M	-31.65M	-73.35M	-53.31M	-78.00M
No. Analysts	-	-	-	-	-	4

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	18.7M
Avg	12.1M
Low	5.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-25.8%
Avg	-51.8%
Low	-80.2%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-2.11
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-